Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162


The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.

Pu Y, Zhao F, Li Y, Cui M, Wang H, Meng X, Cai S.

BMC Cancer. 2017 Jan 10;17(1):45. doi: 10.1186/s12885-016-3002-x.


Regulatory mechanisms of microRNAs in lung cancer stem cells.

Fan T, Wang W, Zhang B, Xu Y, Chen L, Pan S, Hu H, Geng Q.

Springerplus. 2016 Oct 10;5(1):1762. Review.


Changes in the Expression of miR-34a and its Target Genes Following Spinal Cord Injury In Rats.

Chen Y, Cao S, Xu P, Han W, Shan T, Pan J, Lin W, Chen X, Wang X.

Med Sci Monit. 2016 Oct 25;22:3981-3993.


Prioritizing cancer-related microRNAs by integrating microRNA and mRNA datasets.

Jin D, Lee H.

Sci Rep. 2016 Oct 13;6:35350. doi: 10.1038/srep35350.


Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs.

Wang X, Wang C, Zhang X, Hua R, Gan L, Huang M, Zhao L, Ni S, Guo W.

J Hematol Oncol. 2016 Sep 20;9(1):90. doi: 10.1186/s13045-016-0323-9.


MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells.

Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Yamada T, Kudo M, Yue J, Sakuragi N.

J Exp Clin Cancer Res. 2016 Sep 5;35(1):132. doi: 10.1186/s13046-016-0415-y.


Wnt-signalling pathways and microRNAs network in carcinogenesis: experimental and bioinformatics approaches.

Onyido EK, Sweeney E, Nateri AS.

Mol Cancer. 2016 Sep 2;15(1):56. doi: 10.1186/s12943-016-0541-3. Review.


miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis.

Xue J, Zhou A, Wu Y, Morris SA, Lin K, Amin S, Verhaak R, Fuller G, Xie K, Heimberger AB, Huang S.

Cancer Res. 2016 Jul 15;76(14):4293-304. doi: 10.1158/0008-5472.CAN-15-3073.


Notch1 pathway-mediated microRNA-151-5p promotes gastric cancer progression.

Hsu KW, Fang WL, Huang KH, Huang TT, Lee HC, Hsieh RH, Chi CW, Yeh TS.

Oncotarget. 2016 Jun 21;7(25):38036-38051. doi: 10.18632/oncotarget.9342.


Cancer Stem Cells: Dynamic Entities in an Ever-Evolving Paradigm.

Lopez-Bertoni H, Li Y, Laterra J.

Biol Med (Aligarh). 2015 Nov;7(Suppl 2). pii: 001.


Identification of miR-34a-target interactions by a combined network based and experimental approach.

Hart M, Rheinheimer S, Leidinger P, Backes C, Menegatti J, Fehlmann T, Grässer F, Keller A, Meese E.

Oncotarget. 2016 Jun 7;7(23):34288-99. doi: 10.18632/oncotarget.9103.


The influence of miR-34a expression on stemness and cytotoxic susceptibility of breast cancer stem cells.

Zhang H, Li N, Zhang J, Jin F, Shan M, Qin J, Wang Y.

Cancer Biol Ther. 2016 Jun 2;17(6):614-24. doi: 10.1080/15384047.2016.1177678.


Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy.

Han Li C, Chen Y.

Curr Genomics. 2015 Oct;16(5):319-26. doi: 10.2174/1389202916666150707155851.


MicroRNA and extracellular vesicles in glioblastoma: small but powerful.

Rooj AK, Mineo M, Godlewski J.

Brain Tumor Pathol. 2016 Apr;33(2):77-88. doi: 10.1007/s10014-016-0259-3. Review.


MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1.

McCubbrey AL, Nelson JD, Stolberg VR, Blakely PK, McCloskey L, Janssen WJ, Freeman CM, Curtis JL.

J Immunol. 2016 Feb 1;196(3):1366-75. doi: 10.4049/jimmunol.1401838.


MicroRNA-584-3p, a novel tumor suppressor and prognostic marker, reduces the migration and invasion of human glioma cells by targeting hypoxia-induced ROCK1.

Xue H, Guo X, Han X, Yan S, Zhang J, Xu S, Li T, Guo X, Zhang P, Gao X, Liu Q, Li G.

Oncotarget. 2016 Jan 26;7(4):4785-805. doi: 10.18632/oncotarget.6735.


Targeting Notch to overcome radiation resistance.

Yahyanejad S, Theys J, Vooijs M.

Oncotarget. 2016 Feb 16;7(7):7610-28. doi: 10.18632/oncotarget.6714. Review.


Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells.

Cho CY, Huang JS, Shiah SG, Chung SY, Lay JD, Yang YY, Lai GM, Cheng AL, Chen LT, Chuang SE.

RNA. 2016 Feb;22(2):303-15. doi: 10.1261/rna.052571.115.


microRNA-34a as a Therapeutic Agent against Human Cancer.

Saito Y, Nakaoka T, Saito H.

J Clin Med. 2015 Nov 16;4(11):1951-9. doi: 10.3390/jcm4111951. Review.

Items per page

Supplemental Content

Support Center